Interleukin-4 is a participant in the regulation of depressive-like behavior

Behavioural Brain Research

Volumn 326, Issue , 2017, Pages 165-172

  Wachholz, Simone ^a   Knorr, Alexandra ^a   Mengert, Leonie ^a   Plümper, Jennifer ^a   Sommer, Rainer ^a   Juckel, Georg ^a,b   Friebe, Astrid ^a,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Paracelsus Medical University   (Germany)

Author keywords

Animal model; Depression; Interferon alpha; Interleukin 4; Microglia

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTEGRIN; ANTIGEN; CD200 RECEPTOR; CD206 ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CD3+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; DEPRESSION; FORCED SWIM TEST; INFLAMMATION; MALE; MICROGLIA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TAIL SUSPENSION TEST; TH2 CELL; ANIMAL; ANIMAL BEHAVIOR; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; CONDITIONED REFLEX; DEFICIENCY; DISEASE MODEL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CONDITIONING, CLASSICAL; DEPRESSION; DISEASE MODELS, ANIMAL; INTERFERON-ALPHA; INTERLEUKIN-4; MICE; MICE, INBRED BALB C;

EID: 85015735117     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2017.03.020     Document Type: Article

References (43)

1. [1] Howren, M.B., Lamkin, D.M., Suls, J., Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71:2 (2009), 171–186.
2. [2] Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctôt, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67:5 (2010), 446–457.
3. [3] Müller, N., Schwarz, M.J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., Möller, H.J., Arolt, V., Riedel, M., The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 11:7 (2006), 680–684.
4. [4] Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A.A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., Kamalipour, A., Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety 26:7 (2009), 607–611.
5. [5] Abbasi, S.H., Hosseini, F., Modabbernia, A., Ashrafi, M., Akhondzadeh, S., Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J. Affect. Disord. 141:2–3 (2012), 308–314.
6. [6] Fond, G., Hamdani, N., Kapczinski, F., Boukouaci, W., Drancourt, N., Dargel, A., Oliveira, J., Le Guen, E., Marlinge, E., Tamouza, R., Leboyer, M., Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr. Scand. 129:3 (2014), 163–179.
7. [7] Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:1 (2013), 31–41.
8. [8] Faridhosseini, F., Sadeghi, R., Farid, L., Pourgholami, M., Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum. Psychopharmacol. 29:3 (2014), 216–223.
9. [9] Zdilar, D., Franco-Bronson, K., Buchler, N., Locala, J.A., Younossi, Z.M., Hepatitis C, interferon alfa, and depression. Hepatology 31:6 (2000), 1207–1211.
10. [10] Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G.R., Kautz, A., Forton, D., Pariante, C.M., Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J. Hepatol. 57:6 (2012), 1379–1390.
11. [11] Dorr, R.T., Interferon-alpha in malignant and viral diseases. A review. Drugs 45:2 (1993), 177–211.
12. [12] Rizza, P., Moretti, F., Belardelli, F., Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 43:3 (2010), 204–209.
13. [13] Tarhini, A.A., Gogas, H., Kirkwood, J.M., IFN-a in the treatment of melanoma. J. Immunol. 189 (2012), 3789–3793.
14. [14] Salzet, M., Vieau, D., Day, R., Crosstalk between nervous and immune systems through the animal kingdom: focus on opioids. Trends Neurosci. 23 (2000), 550–555.
15. [15] Nimmerjahn, A., Kirchhoff, F., Helmchen, F., Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308 (2005), 1314–1318.
16. [16] Wake, H., Moorhouse, A.J., Jinno, S., Kohsaka, S., Nabekura, J., Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. Neurosci. 29:13 (2009), 3974–3980.
17. [17] Kettenmann, H., Kirchhoff, F., Verkhratsky, A., Microglia: new roles for the synaptic stripper. Neuron 77:1 (2013), 10–18.
18. [18] Van Rossum, D., Hanisch, U., Microglia. Metab. Brain Dis. 19:3–4 (2004), 393–411.
19. [19] Stence, N., Waite, M., Dailey, M.E., Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. Glia 33:3 (2001), 256–266.
20. [20] Kreutzberg, G.W., Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19 (1996), 312–318.
21. [21] Kettenmann, H., Hanisch, U.K., Noda, M., Verkhratsky, A., Physiology of microglia. Physiol. Rev. 91 (2011), 461–553.
22. [22] Chhor, V., Le Charpentier, T., Lebon, S., Oré, M.V., Celador, I.L., Josserand, J., Degos, V., Jacotot, E., Hagberg, H., Sävman, K., Mallard, C., Gressens, P., Fleiss, B., Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav. Immun. 32 (2013), 70–85.
23. [23] Mantovani, A., From phagocyte diversity and activation to probiotics: back to Metchnikoff. Eur. J. Immunol. 38:12 (2008), 3269–3273.
24. [24] Koning, N., Uitdehaag, B.M., Huitinga, I., Hoek, R.M., Restoring immune suppression in the multiple sclerosis brain. Prog. Neurobiol. 89:4 (2009), 359–368.
25. [25] Wachholz, S., Eßlinger, M., Plümper, J., Manitz, M.P., Juckel, G., Friebe, A., Microglia activation is associated with IFN-α induced depressive-like behavior. Brain Behav. Immun. 55:July (2016), 105–113.
26. [26] Ramamoorthy, S., Ramamoorthy, J.D., Prasad, P.D., Bhat, G.K., Mahesh, V.B., Leibach, F.H., Ganapathy, V., Regulation of the human serotonin transporter by interleukin-1 beta. Biochem. Biophys. Res. Commun. 216:2 (1995), 560–567.
27. [27] Morikawa, O., Sakai, N., Obara, H., Saito, N., Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur. J. Pharmacol. 349:2–3 (1998), 317–324.
28. [28] Mössner, R., Heils, A., Stöber, G., Okladnova, O., Daniel, S., Lesch, K.P., Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem. Int. 33:3 (1998), 251–254.
29. [29] Mössner, R., Daniel, S., Schmitt, A., Albert, D., Lesch, K.P., Modulation of serotonin transporter function by interleukin-4. Life Sci. 68:8 (2001), 873–880.
30. [30] Campanella, M., Sciorati, C., Tarozzo, G., Beltramo, M., Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke 33 (2002), 586–592.
31. [31] Gadani, S.P., Cronk, J.C., Norris, G.T., Kipnis, J., IL-4 in the brain: a cytokine to remember. J. Immunol. 189 (2012), 4213–4219.
32. [32] Mori, S., Maher, P., Conti, B., Neuroimmunology of the interleukins 13 and 4. Brain Sci., 6(2), 2016, 18.
33. [33] Ponomarev, E.D., Maresz, K., Tan, Y., Dittel, B.N., CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J. Neurosci. 27:40 (2007), 10714–10721.
34. [34] Park, H.J., Shim, H.S., An, K., Starkweather, A., Kim, K.S., Shim, I., IL-4 inhibits IL-1β-induced depressive-like behavior and central neurotransmitter alterations. Mediators Inflamm., 2015, 2015, 941413.
35. [35] Qiu, D., Li, X.N., Pioglitazone inhibits the secretion of proinflammatory cytokines and chemokines in astrocytes stimulated with lipopolysaccharide. Int. J. Clin. Pharmacol. Ther. 53:9 (2015), 746–752.
36. [36] Zhao, X., Wang, H., Sun, G., Zhang, J., Edwards, N.J., Aranowski, J., Neuronal interleukin-4 as a model of microglial pathways and ischemic brain damage. J. Neurosci. 35:32 (2015), 11281–11291.
37. [37] Lee, H.J., Park, H.J., Starkweather, A., An, K., Shim, I., Decreased interleukin-4 release from the neurons of the locus coeruleus in response to immobilization stress. Mediat. Inflamm., 2016, 2016, 3501905.
38. [38] Moon, M.L., Joesting, J.J., Blevins, N.A., Lawson, M.A., Gainey, S.J., Towers, A.E., Mc Neil, L.K., Freund, G.G., IL-4 knock out mice display anxiety-like behavior. Behav. Genet. 45:4 (2015), 451–460.
39. [39] Carneiro, A.M., Airey, D.C., Thompson, B., Zhu, C.B., Lu, L., Chesler, E.J., Erikson, K.M., Blakely, R.D., Functional coding variation in recombinant inbred mouse lines reveals multiple serotonin transporter-associated phenotypes. Proc. Natl. Acad. Sci. U. S. A. 106:6 (2009), 2047–2052.
40. [40] Derecki, N.C., Cardani, A.N., Yang, C.H., Quinnies, K.M., Crihfield, A., Lynch, K.R., Kipnis, J., Regulation of learning and memory by meningeal immunity: a key role for IL-4. J. Exp. Med. 207:5 (2010), 1067–1080.
41. [41] Derecki, N.C., Quinnies, K.M., Kipnis, J., Alternatively activated myeloid (M2) cells enhance cognitive function in immune compromised mice. Brain Behav. Immun. 25:3 (2011), 379–385.
42. [42] Hart, P.H., Bonder, C.S., Jones, C.A., Finlay-Jones, J.J., Control of major histocompatibility complex class II expression on human monocytes by interleukin-4: regulatory effect of lipopolysaccharide. Immunology 89:4 (1996), 599–605.
43. [43] Reith, W., Leibund Gut-Landmann, S., Waldburger, J.M., Regulation of MHC class II gene expression by the class II transactivator. Nat. Rev. Immunol. 5:10 (2005), 793–806.